Aldo Maggioni to Double-Blind Method
This is a "connection" page, showing publications Aldo Maggioni has written about Double-Blind Method.
Connection Strength
0.402
-
Relation between weight loss and causes of death in patients with cardiovascular disease: finding from the SCOUT trial. J Cardiovasc Med (Hagerstown). 2017 Mar; 18(3):144-151.
Score: 0.074
-
Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2019 10 24; 381(17):1609-1620.
Score: 0.022
-
Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease. Circulation. 2019 08 13; 140(7):529-537.
Score: 0.022
-
Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. Gastroenterology. 2019 09; 157(3):682-691.e2.
Score: 0.022
-
Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial. Gastroenterology. 2019 08; 157(2):403-412.e5.
Score: 0.021
-
Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial). Am J Cardiol. 2018 07 15; 122(2):255-260.
Score: 0.020
-
Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes. Eur J Heart Fail. 2018 05; 20(5):888-895.
Score: 0.020
-
Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study. Eur J Heart Fail. 2018 02; 20(2):268-277.
Score: 0.019
-
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2017 09 28; 377(13):1228-1239.
Score: 0.019
-
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017 10 05; 377(14):1319-1330.
Score: 0.019
-
Prognostic Impact of Diabetes and Prediabetes on Survival Outcomes in Patients With Chronic Heart Failure: A Post-Hoc Analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) Trial. J Am Heart Assoc. 2017 Jul 05; 6(7).
Score: 0.019
-
Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. JACC Heart Fail. 2017 07; 5(7):471-482.
Score: 0.019
-
Patient-reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study. Eur J Heart Fail. 2017 06; 19(6):782-791.
Score: 0.019
-
Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. Eur Heart J. 2017 04 14; 38(15):1119-1127.
Score: 0.019
-
Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure. N Engl J Med. 2017 05 18; 376(20):1956-1964.
Score: 0.019
-
Clinical and prognostic value of spot urinary creatinine in chronic heart failure-An analysis from GISSI-HF. Am Heart J. 2017 Jun; 188:189-195.
Score: 0.019
-
Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). Am Heart J. 2017 May; 187:1-9.
Score: 0.018
-
Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome. Am Heart J. 2011 Oct; 162(4):613-619.e1.
Score: 0.013